VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q64605553  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000232.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q64605553‏
024 ‎‡a  0000-0002-2527-5428‏ ‎‡2  orcid‏
024 ‎‡a  57186794800‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q64605553‏
100 0 ‎‡a  David M Thomas‏ ‎‡9  it‏ ‎‡9  es‏ ‎‡9  ast‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  ডেভিড এম টমাস‏ ‎‡9  bn‏
400 0 ‎‡a  David M Thomas‏ ‎‡c  researcher ORCID 0000-0002-2527-5428‏ ‎‡9  en‏
400 0 ‎‡a  David M Thomas‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics‏
670 ‎‡a  Author's A candidate gene approach to searching for low-penetrance breast and prostate cancer genes‏
670 ‎‡a  Author's A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings‏
670 ‎‡a  Author's A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma‏
670 ‎‡a  Author's A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions.‏
670 ‎‡a  Author's A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma‏
670 ‎‡a  Author's A quantitative model to predict pathogenicity of missense variants in the TP53 gene‏
670 ‎‡a  Author's A role for alphaV integrin subunit in TGF-beta-stimulated osteoclastogenesis‏
670 ‎‡a  Author's A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia‏
670 ‎‡a  Author's Abstract 4593: Genome-wide association study identifies novel loci associated with osteosarcoma‏
670 ‎‡a  Author's Abstracts‏
670 ‎‡a  Author's Abstracts of the 10th Congress of the European Association of NeuroOncology. Marseille, France. September 6-9, 2012‏
670 ‎‡a  Author's Accepting risk in the acceleration of drug development for rare cancers‏
670 ‎‡a  Author's Adolescent and young adult cancer: a revolution in evolution?‏
670 ‎‡a  Author's Adolescent and Young Adult Oncology: An Emerging Field‏
670 ‎‡a  Author's Adolescents and young adults with cancer: the challenge‏
670 ‎‡a  Author's An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development‏
670 ‎‡a  Author's Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types‏
670 ‎‡a  Author's Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.‏
670 ‎‡a  Author's Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases.‏
670 ‎‡a  Author's Author Correction: Diagnosis of fusion genes using targeted RNA sequencing‏
670 ‎‡a  Author's Author Correction: Therapeutic implications of germline genetic findings in cancer‏
670 ‎‡a  Author's Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis‏
670 ‎‡a  Author's Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set‏
670 ‎‡a  Author's Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis‏
670 ‎‡a  Author's Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine.‏
670 ‎‡a  Author's "Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic‏
670 ‎‡a  Author's Cancer-associated neochromosomes: a novel mechanism of oncogenesis.‏
670 ‎‡a  Author's Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae.‏
670 ‎‡a  Author's Clinical implications of genomics for cancer risk genetics‏
670 ‎‡a  Author's Clinical Overview of MDM2/X-Targeted Therapies‏
670 ‎‡a  Author's ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data‏
670 ‎‡a  Author's Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium‏
670 ‎‡a  Author's Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3).‏
670 ‎‡a  Author's Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis‏
670 ‎‡a  Author's Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing‏
670 ‎‡a  Author's Counterpoints in cancer: the somatic mutation theory under attack‏
670 ‎‡a  Author's Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology‏
670 ‎‡a  Author's Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions‏
670 ‎‡a  Author's Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.‏
670 ‎‡a  Author's Cyclin E1 is amplified and overexpressed in osteosarcoma.‏
670 ‎‡a  Author's Dendritic cell immunotherapy for stage IV melanoma‏
670 ‎‡a  Author's Denosumab: a new treatment option for giant cell tumor of bone.‏
670 ‎‡a  Author's Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.‏
670 ‎‡a  Author's Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone‏
670 ‎‡a  Author's Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk‏
670 ‎‡a  Author's Dexamethasone modulates insulin receptor expression and subcellular distribution of the glucose transporter GLUT 1 in UMR 106-01, a clonal osteogenic sarcoma cell line.‏
670 ‎‡a  Author's Diagnosis and Management of Hereditary Sarcoma.‏
670 ‎‡a  Author's Diagnosis of fusion genes using targeted RNA sequencing‏
670 ‎‡a  Author's Distinguishing activity from progress.‏
670 ‎‡a  Author's Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.‏
670 ‎‡a  Author's Epigenetic modifications in osteogenic differentiation and transformation.‏
670 ‎‡a  Author's Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.‏
670 ‎‡a  Author's Etiologic, environmental and inherited risk factors in sarcomas.‏
670 ‎‡a  Author's Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk‏
670 ‎‡a  Author's Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas‏
670 ‎‡a  Author's Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma.‏
670 ‎‡a  Author's FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.‏
670 ‎‡a  Author's FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center‏
670 ‎‡a  Author's Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood‏
670 ‎‡a  Author's Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood.‏
670 ‎‡a  Author's Gene expression profiling of sarcomas‏
670 ‎‡a  Author's Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients‏
670 ‎‡a  Author's Genome-wide association study identifies two susceptibility loci for osteosarcoma‏
670 ‎‡a  Author's Genome-wide association study of prostate cancer identifies a second risk locus at 8q24‏
670 ‎‡a  Author's Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases.‏
670 ‎‡a  Author's Giant cell tumour of bone.‏
670 ‎‡a  Author's High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.‏
670 ‎‡a  Author's Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts‏
670 ‎‡a  Author's Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation‏
670 ‎‡a  Author's Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials‏
670 ‎‡a  Author's Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice.‏
670 ‎‡a  Author's Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33‏
670 ‎‡a  Author's Insulin receptor expression in primary and cultured osteoclast-like cells‏
670 ‎‡a  Author's Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.‏
670 ‎‡a  Author's International survey of awareness of genetic risk in the clinical sarcoma community‏
670 ‎‡a  Author's Is Li-Fraumeni syndrome really much more common?‏
670 ‎‡a  Author's Lessons from the deep study of rare tumours‏
670 ‎‡a  Author's Li-Fraumeni syndrome: cancer risk assessment and clinical management‏
670 ‎‡a  Author's Liposarcoma: molecular genetics and therapeutics.‏
670 ‎‡a  Author's Locally Aggressive Connective Tissue Tumors.‏
670 ‎‡a  Author's Lung cancer in motor exhaust-related occupations‏
670 ‎‡a  Author's Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines.‏
670 ‎‡a  Author's Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary‏
670 ‎‡a  Author's Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation‏
670 ‎‡a  Author's Medical Research Council adjuvant trial in high-grade gliomas‏
670 ‎‡a  Author's Molecular medicine: a clinician's primer on microarrays.‏
670 ‎‡a  Author's Molecular pathogenesis of osteosarcoma.‏
670 ‎‡a  Author's Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB‏
670 ‎‡a  Author's Monogenic and polygenic determinants of sarcoma risk: an international genetic study‏
670 ‎‡a  Author's Mouse Models of Tumor Immunotherapy‏
670 ‎‡a  Author's MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer‏
670 ‎‡a  Author's Multidisciplinary approach to diagnosis and management of osteosarcoma - a review of the St Vincent's Hospital experience.‏
670 ‎‡a  Author's Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual.‏
670 ‎‡a  Author's Next-generation sequence analysis of cancer xenograft models.‏
670 ‎‡a  Author's Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling‏
670 ‎‡a  Author's Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer.‏
670 ‎‡a  Author's Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse‏
670 ‎‡a  Author's Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ.‏
670 ‎‡a  Author's Patient perspectives on molecular tumor profiling: "Why wouldn't you?"‏
670 ‎‡a  Author's Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes‏
670 ‎‡a  Author's Possible pro-carcinogenic effect of endotoxin on lung cancer in an extended follow-up of Shanghai women textile workers‏
670 ‎‡a  Author's PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma‏
670 ‎‡a  Author's Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial‏
670 ‎‡a  Author's Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma.‏
670 ‎‡a  Author's Progress in management of acute myeloid leukaemia‏
670 ‎‡a  Author's Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective study‏
670 ‎‡a  Author's Prolonged disease-free survival with specific re-induction therapy in acute myeloid leukaemia relapsing following bone marrow transplantation‏
670 ‎‡a  Author's Proportion of lung cancers in males, due to occupation, in different areas of the USA.‏
670 ‎‡a  Author's Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?‏
670 ‎‡a  Author's Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.‏
670 ‎‡a  Author's RANKL, denosumab, and giant cell tumor of bone.‏
670 ‎‡a  Author's RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma‏
670 ‎‡a  Author's RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer‏
670 ‎‡a  Author's RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model‏
670 ‎‡a  Author's Retrospective survey of unselected hospital patients with and without cancer comparing outcomes following venous thromboembolism‏
670 ‎‡a  Author's Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study‏
670 ‎‡a  Author's Safety of denosumab in giant-cell tumour of bone‏
670 ‎‡a  Author's Sarcoma and germ-line DICER1 mutations - Authors' reply.‏
670 ‎‡a  Author's Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing‏
670 ‎‡a  Author's Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review‏
670 ‎‡a  Author's Starting an adolescent and young adult program: some success stories and some obstacles to overcome.‏
670 ‎‡a  Author's STI-571 inhibits in vitro angiogenesis.‏
670 ‎‡a  Author's Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets.‏
670 ‎‡a  Author's Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma‏
670 ‎‡a  Author's Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.‏
670 ‎‡a  Author's Surveillance recommendations for patients with germline TP53 mutations.‏
670 ‎‡a  Author's Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells‏
670 ‎‡a  Author's Synchronous diagnosis of Hodgkin lymphoma and osteosarcoma‏
670 ‎‡a  Author's Targeting the p53 Pathway in Ewing Sarcoma.‏
670 ‎‡a  Author's Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma‏
670 ‎‡a  Author's The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology‏
670 ‎‡a  Author's The distinctive biology of cancer in adolescents and young adults.‏
670 ‎‡a  Author's The growing problem of benign connective tissue tumours.‏
670 ‎‡a  Author's The hard and soft sides of cancer programming‏
670 ‎‡a  Author's The Hippo pathway and human cancer.‏
670 ‎‡a  Author's The life history of neochromosomes revealed.‏
670 ‎‡a  Author's The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design‏
670 ‎‡a  Author's The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly‏
670 ‎‡a  Author's The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts‏
670 ‎‡a  Author's The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.‏
670 ‎‡a  Author's The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.‏
670 ‎‡a  Author's The relationship between unmet needs and distress amongst young people with cancer.‏
670 ‎‡a  Author's The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation‏
670 ‎‡a  Author's The STATs in cell stress-type responses‏
670 ‎‡a  Author's Therapeutic implications of germline genetic findings in cancer‏
670 ‎‡a  Author's Timing and context: important considerations in the return of genetic results to research participants‏
670 ‎‡a  Author's Translating genomic risk into an early detection strategy for sarcoma‏
670 ‎‡a  Author's Translational biology of osteosarcoma‏
670 ‎‡a  Author's Who should access germline genome sequencing? A mixed methods study of patient views‏
670 ‎‡a  Author's Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer‏
670 ‎‡a  Author's Wiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence.‏
670 ‎‡a  Author's Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice‏
670 ‎‡a  Author's Wnts, bone and cancer.‏
670 ‎‡a  Author's সারাংশপত্র‏
909 ‎‡a  (orcid) 0000000225275428‏ ‎‡9  1‏
909 ‎‡a  (scopus) 57186794800‏ ‎‡9  1‏
912 ‎‡a  imputationandsubsetbasedassociationanalysisacrossdifferentcancertypesidentifiesmultipleindependentrisklociinthetertclptm1lregiononchromosome5p1533‏ ‎‡A  Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33‏ ‎‡9  1‏
912 ‎‡a  evaluationofvariationinthephosphoinositide3kinasecatalyticsubunitalphaoncogeneandbreastcancerrisk‏ ‎‡A  Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk‏ ‎‡9  1‏
912 ‎‡a  সরশপতর‏ ‎‡A  সারাংশপত্র‏ ‎‡9  1‏
912 ‎‡a  analysisofheritabilityandsharedheritabilitybasedongenomewideassociationstudiesfor13cancertypes‏ ‎‡A  Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types‏ ‎‡9  1‏
912 ‎‡a  abstracts‏ ‎‡A  Abstracts‏ ‎‡9  1‏
919 ‎‡a  51fraumenisyndromecancerriskassessmentandclinicalmanagement‏ ‎‡A  Li-Fraumeni syndrome: cancer risk assessment and clinical management‏ ‎‡9  1‏
919 ‎‡a  lungcancerinmotorexhaustrelatedoccupations‏ ‎‡A  Lung cancer in motor exhaust-related occupations‏ ‎‡9  1‏
919 ‎‡a  lessonsfromthedeepstudyofraretumours‏ ‎‡A  Lessons from the deep study of rare tumours‏ ‎‡9  1‏
919 ‎‡a  is51fraumenisyndromereallymuchmorecommon‏ ‎‡A  Is Li-Fraumeni syndrome really much more common?‏ ‎‡9  1‏
919 ‎‡a  internationalsurveyofawarenessofgeneticriskintheclinicalsarcomacommunity‏ ‎‡A  International survey of awareness of genetic risk in the clinical sarcoma community‏ ‎‡9  1‏
919 ‎‡a  integratedmutationcopynumberandexpressionprofilinginresectablenonsmallcelllungcancer‏ ‎‡A  Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.‏ ‎‡9  1‏
919 ‎‡a  insulinreceptorexpressioninprimaryandculturedosteoclastlikecells‏ ‎‡A  Insulin receptor expression in primary and cultured osteoclast-like cells‏ ‎‡9  1‏
919 ‎‡a  managementofsarcomaintheasiapacificregionresourcestratifiedguidelines‏ ‎‡A  Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines.‏ ‎‡9  1‏
919 ‎‡a  translationalbiologyofosteosarcoma‏ ‎‡A  Translational biology of osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  impairedbonedevelopmentandincreasedmesenchymalprogenitorcellsincalvariaofrb1mice‏ ‎‡A  Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice.‏ ‎‡9  1‏
919 ‎‡a  impactofyoungageontreatmentefficacyandsafetyinadvancedcolorectalcancerapooledanalysisofpatientsfrom91linephase3chemotherapytrials‏ ‎‡A  Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials‏ ‎‡9  1‏
919 ‎‡a  translatinggenomicriskintoanearlydetectionstrategyforsarcoma‏ ‎‡A  Translating genomic risk into an early detection strategy for sarcoma‏ ‎‡9  1‏
919 ‎‡a  timingandcontextimportantconsiderationsinthereturnofgeneticresultstoresearchparticipants‏ ‎‡A  Timing and context: important considerations in the return of genetic results to research participants‏ ‎‡9  1‏
919 ‎‡a  therapeuticimplicationsofgermlinegeneticfindingsincancer‏ ‎‡A  Therapeutic implications of germline genetic findings in cancer‏ ‎‡9  1‏
919 ‎‡a  immuneresponsetorb1regulatedsenescencelimitsradiationinducedosteosarcomaformation‏ ‎‡A  Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation‏ ‎‡9  1‏
919 ‎‡a  identificationofnovelsarcomariskgenesusinga2stagegenomewidednasequencingstrategyincancerclusterfamiliesandpopulationcaseandcontrolcohorts‏ ‎‡A  Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts‏ ‎‡9  1‏
919 ‎‡a  highresolutionmeltinganalysisfortherapidandsensitivedetectionofmutationsinclinicalsampleskrascodon12and13mutationsinnonsmallcelllungcancer‏ ‎‡A  High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.‏ ‎‡9  1‏
919 ‎‡a  giantcelltumourofbone‏ ‎‡A  Giant cell tumour of bone.‏ ‎‡9  1‏
919 ‎‡a  statsincellstresstyperesponses‏ ‎‡A  The STATs in cell stress-type responses‏ ‎‡9  1‏
919 ‎‡a  retinoblastomaproteinactsasatranscriptionalcoactivatorrequiredforosteogenicdifferentiation‏ ‎‡A  The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation‏ ‎‡9  1‏
919 ‎‡a  relationshipbetweenunmetneedsanddistressamongstyoungpeoplewithcancer‏ ‎‡A  The relationship between unmet needs and distress amongst young people with cancer.‏ ‎‡9  1‏
919 ‎‡a  genomicstratificationandliquidbiopsyinarareadrenocorticalcarcinomaacccasewithduallungmetastases‏ ‎‡A  Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases.‏ ‎‡9  1‏
919 ‎‡a  genomewideassociationstudyofprostatecanceridentifiesa2risklocusat8q24‏ ‎‡A  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24‏ ‎‡9  1‏
919 ‎‡a  promiseofpetinclinicalmanagementandasasensitivetestfordrugcytotoxicityinsarcomas‏ ‎‡A  The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.‏ ‎‡9  1‏
919 ‎‡a  genomewideassociationstudyidentifies2susceptibilitylociforosteosarcoma‏ ‎‡A  Genome-wide association study identifies two susceptibility loci for osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  genomewideassociationstudyidentifiesthegldcil33locusassociatedwithsurvivalofosteosarcomapatients‏ ‎‡A  Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients‏ ‎‡9  1‏
919 ‎‡a  pigeonprojectprotocolofalongitudinalstudyexaminingpsychosocialandethicalissuesandoutcomesingermlinegenomicsequencingforcancer‏ ‎‡A  The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.‏ ‎‡9  1‏
919 ‎‡a  geneexpressionprofilingofsarcomas‏ ‎‡A  Gene expression profiling of sarcomas‏ ‎‡9  1‏
919 ‎‡a  genderspecificactivityofchemotherapycorrelateswithoutcomesinchemosensitivecancersofyoungadulthood‏ ‎‡A  Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood.‏ ‎‡9  1‏
919 ‎‡a  genderdifferencesindoxorubicinpharmacologyforsubjectswithchemosensitivecancersofyoungadulthood‏ ‎‡A  Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood‏ ‎‡9  1‏
919 ‎‡a  fishanalysisofselectedsofttissuetumorsdiagnosticexperienceinatertiarycenter‏ ‎‡A  FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center‏ ‎‡9  1‏
919 ‎‡a  fgfrgeneticalterationspredictforsensitivitytonvpbgj398aselectivepanfgfrinhibitor‏ ‎‡A  FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.‏ ‎‡9  1‏
919 ‎‡a  femoralmesenchymalchondrosarcomawithsecondaryaneurysmalbonecystsmimickingasmallcellosteosarcoma‏ ‎‡A  Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma.‏ ‎‡9  1‏
919 ‎‡a  expressionoflymphocyteimmunoregulatorybiomarkersinboneandsofttissuesarcomas‏ ‎‡A  Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas‏ ‎‡9  1‏
919 ‎‡a  etiologicenvironmentalandinheritedriskfactorsinsarcomas‏ ‎‡A  Etiologic, environmental and inherited risk factors in sarcomas.‏ ‎‡9  1‏
919 ‎‡a  estimatingtp53mutationcarrierprobabilityinfamilieswith51fraumenisyndromeusinglfspro‏ ‎‡A  Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.‏ ‎‡9  1‏
919 ‎‡a  epigeneticmodificationsinosteogenicdifferentiationandtransformation‏ ‎‡A  Epigenetic modifications in osteogenic differentiation and transformation.‏ ‎‡9  1‏
919 ‎‡a  efficacyofimatinibmesylateforthetreatmentoflocallyadvancedandormetastatictenosynovialgiantcelltumorpigmentedvillonodularsynovitis‏ ‎‡A  Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.‏ ‎‡9  1‏
919 ‎‡a  distinguishingactivityfromprogress‏ ‎‡A  Distinguishing activity from progress.‏ ‎‡9  1‏
919 ‎‡a  oncogenicpropertiesofewswt1ofdesmoplasticsmallroundcelltumorsareunmaskedbylossofp53inmurineembryonicfibroblasts‏ ‎‡A  The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts‏ ‎‡9  1‏
919 ‎‡a  diagnosisoffusiongenesusingtargetedrnasequencing‏ ‎‡A  Diagnosis of fusion genes using targeted RNA sequencing‏ ‎‡9  1‏
919 ‎‡a  medicalgenomereferencebankcontainswholegenomeandphenotypedataof2570healthyelderly‏ ‎‡A  The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly‏ ‎‡9  1‏
919 ‎‡a  medicalgenomereferencebankawholegenomedataresourceof4000healthyelderlyindividualsrationaleandcohortdesign‏ ‎‡A  The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design‏ ‎‡9  1‏
919 ‎‡a  diagnosisandmanagementofhereditarysarcoma‏ ‎‡A  Diagnosis and Management of Hereditary Sarcoma.‏ ‎‡9  1‏
919 ‎‡a  lifehistoryofneochromosomesrevealed‏ ‎‡A  The life history of neochromosomes revealed.‏ ‎‡9  1‏
919 ‎‡a  hippopathwayandhumancancer‏ ‎‡A  The Hippo pathway and human cancer.‏ ‎‡9  1‏
919 ‎‡a  hardandsoftsidesofcancerprogramming‏ ‎‡A  The hard and soft sides of cancer programming‏ ‎‡9  1‏
919 ‎‡a  growingproblemofbenignconnectivetissuetumours‏ ‎‡A  The growing problem of benign connective tissue tumours.‏ ‎‡9  1‏
919 ‎‡a  dexamethasonemodulatesinsulinreceptorexpressionandsubcellulardistributionoftheglucosetransporterglut1inumr10601aclonalosteogenicsarcomacellline‏ ‎‡A  Dexamethasone modulates insulin receptor expression and subcellular distribution of the glucose transporter GLUT 1 in UMR 106-01, a clonal osteogenic sarcoma cell line.‏ ‎‡9  1‏
919 ‎‡a  developmentandpilottestingofadecisionaidforgenomicresearchparticipantsnotifiedofclinicallyactionableresearchfindingsforcancerrisk‏ ‎‡A  Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk‏ ‎‡9  1‏
919 ‎‡a  distinctivebiologyofcancerinadolescentsandyoungadults‏ ‎‡A  The distinctive biology of cancer in adolescents and young adults.‏ ‎‡9  1‏
919 ‎‡a  denosumabinducestumorreductionandboneformationinpatientswithgiantcelltumorofbone‏ ‎‡A  Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone‏ ‎‡9  1‏
919 ‎‡a  whoshouldaccessgermlinegenomesequencingamixedmethodsstudyofpatientviews‏ ‎‡A  Who should access germline genome sequencing? A mixed methods study of patient views‏ ‎‡9  1‏
919 ‎‡a  wholegenometranscriptomeandmethylomeprofilingenhancesactionabletargetdiscoveryinhighriskpediatriccancer‏ ‎‡A  Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer‏ ‎‡9  1‏
919 ‎‡a  wikibasedclinicalpracticeguidelinesforthemanagementofadultonsetsarcomaanewparadigminsarcomaevidence‏ ‎‡A  Wiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence.‏ ‎‡9  1‏
919 ‎‡a  wntinhibitoryfactor1isepigeneticallysilencedinhumanosteosarcomaandtargeteddisruptionacceleratesosteosarcomagenesisinmice‏ ‎‡A  Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice‏ ‎‡9  1‏
919 ‎‡a  wntsboneandcancer‏ ‎‡A  Wnts, bone and cancer.‏ ‎‡9  1‏
919 ‎‡a  denosumabinpatientswithgiantcelltumourofboneanopenlabelphase2study‏ ‎‡A  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.‏ ‎‡9  1‏
919 ‎‡a  denosumabanewtreatmentoptionforgiantcelltumorofbone‏ ‎‡A  Denosumab: a new treatment option for giant cell tumor of bone.‏ ‎‡9  1‏
919 ‎‡a  dendriticcellimmunotherapyforstage4melanoma‏ ‎‡A  Dendritic cell immunotherapy for stage IV melanoma‏ ‎‡9  1‏
919 ‎‡a  cycline1isamplifiedandoverexpressedinosteosarcoma‏ ‎‡A  Cyclin E1 is amplified and overexpressed in osteosarcoma.‏ ‎‡9  1‏
919 ‎‡a  currentconceptsandfutureperspectivesinretroperitonealsofttissuesarcomamanagement‏ ‎‡A  Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.‏ ‎‡9  1‏
919 ‎‡a  crossoncopanelstudyrevealshighsensitivityandaccuracywithoverallanalyticalperformancedependingongenomicregions‏ ‎‡A  Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions‏ ‎‡9  1‏
919 ‎‡a  criteriabasedcurationofatherapyfocusedcompendiumtosupporttreatmentrecommendationsinprecisiononcology‏ ‎‡A  Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology‏ ‎‡9  1‏
919 ‎‡a  counterpointsincancerthesomaticmutationtheoryunderattack‏ ‎‡A  Counterpoints in cancer: the somatic mutation theory under attack‏ ‎‡9  1‏
919 ‎‡a  breakthroughgenerationsstudydesignofalongtermukcohortstudytoinvestigatebreastcanceraetiology‏ ‎‡A  The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology‏ ‎‡9  1‏
919 ‎‡a  terminalosteoblastdifferentiationmediatedbyrunx2andp27kip1isdisruptedinosteosarcoma‏ ‎‡A  Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  costeffectivenessofprecisionmedicineinthe4linetreatmentofmetastaticlungadenocarcinomaanearlydecisionanalyticmodelofmultiplextargetedsequencing‏ ‎‡A  Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing‏ ‎‡9  1‏
919 ‎‡a  comprehensivemappingofp53pathwayalterationsrevealsanapparentroleforbothsnp309andmdm2amplificationinsarcomagenesis‏ ‎‡A  Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis‏ ‎‡9  1‏
919 ‎‡a  comprehensiveanalysisofhormoneandgeneticvariationin36genesrelatedtosteroidhormonemetabolisminpreandpostmenopausalwomenfromthebreastandprostatecancercohortconsortiumbpc3‏ ‎‡A  Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3).‏ ‎‡9  1‏
919 ‎‡a  comprehensiveanalysisofhormoneandgeneticvariationin36genesrelatedtosteroidhormonemetabolisminpreandpostmenopausalwomenfromthebreastandprostatecancercohortconsortium‏ ‎‡A  Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium‏ ‎‡9  1‏
919 ‎‡a  targetingthep53pathwayinewingsarcoma‏ ‎‡A  Targeting the p53 Pathway in Ewing Sarcoma.‏ ‎‡9  1‏
919 ‎‡a  synchronousdiagnosisofhodgkinlymphomaandosteosarcoma‏ ‎‡A  Synchronous diagnosis of Hodgkin lymphoma and osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  sustainedlowdosetreatmentwiththehistonedeacetylaseinhibitorlbh589inducesterminaldifferentiationofosteosarcomacells‏ ‎‡A  Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells‏ ‎‡9  1‏
919 ‎‡a  surveillancerecommendationsforpatientswithgermlinetp53mutations‏ ‎‡A  Surveillance recommendations for patients with germline TP53 mutations.‏ ‎‡9  1‏
919 ‎‡a  clinsvclinicalgradestructuralandcopynumbervariantdetectionfromwholegenomesequencingdata‏ ‎‡A  ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data‏ ‎‡9  1‏
919 ‎‡a  clinicaloverviewofmdm210targetedtherapies‏ ‎‡A  Clinical Overview of MDM2/X-Targeted Therapies‏ ‎‡9  1‏
919 ‎‡a  clinicalimplicationsofgenomicsforcancerriskgenetics‏ ‎‡A  Clinical implications of genomics for cancer risk genetics‏ ‎‡9  1‏
919 ‎‡a  surveillanceingermlinetp53mutationcarriersutilizingwholebodymagneticresonanceimaging‏ ‎‡A  Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.‏ ‎‡9  1‏
919 ‎‡a  chemicalgeneticsofrapamycininsensitivetorc2inscerevisiae‏ ‎‡A  Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae.‏ ‎‡9  1‏
919 ‎‡a  cancerassociatedneochromosomesanovelmechanismofoncogenesis‏ ‎‡A  Cancer-associated neochromosomes: a novel mechanism of oncogenesis.‏ ‎‡9  1‏
919 ‎‡a  cancer2015aprospectivepopulationbasedcancercohortphase1feasibilityofgenomicsguidedprecisionmedicineintheclinic‏ ‎‡A  "Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic‏ ‎‡9  1‏
919 ‎‡a  cancer2015alongitudinalwholeofsystemstudyofgenomiccancermedicine‏ ‎‡A  Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine.‏ ‎‡9  1‏
919 ‎‡a  benefitsandadverseeventsinyoungerversusolderpatientsreceivingneoadjuvantchemotherapyforosteosarcomafindingsfromametaanalysis‏ ‎‡A  Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis‏ ‎‡9  1‏
919 ‎‡a  studyingtheroleoftheimmunesystemontheantitumoractivityofahedgehoginhibitoragainstmurineosteosarcoma‏ ‎‡A  Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  stressinducedcellularadaptivestrategiesancientevolutionarilyconservedprogramsasnewanticancertherapeutictargets‏ ‎‡A  Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets.‏ ‎‡9  1‏
919 ‎‡a  sti571inhibitsinvitroangiogenesis‏ ‎‡A  STI-571 inhibits in vitro angiogenesis.‏ ‎‡9  1‏
919 ‎‡a  startinganadolescentandyoungadultprogramsomesuccessstoriesandsomeobstaclestoovercome‏ ‎‡A  Starting an adolescent and young adult program: some success stories and some obstacles to overcome.‏ ‎‡9  1‏
919 ‎‡a  sociodemographicpsychosocialandclinicalfactorsassociatedwithuptakeofgeneticcounsellingforhereditarycancerasystematicreview‏ ‎‡A  Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review‏ ‎‡9  1‏
919 ‎‡a  sequenceartefactsinaprospectiveseriesofformalinfixedtumourstestedformutationsinhotspotregionsbymassivelyparallelsequencing‏ ‎‡A  Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing‏ ‎‡9  1‏
919 ‎‡a  sarcomaandgermlinedicer1mutationsauthorsreply‏ ‎‡A  Sarcoma and germ-line DICER1 mutations - Authors' reply.‏ ‎‡9  1‏
919 ‎‡a  safetyofdenosumabingiantcelltumourofbone‏ ‎‡A  Safety of denosumab in giant-cell tumour of bone‏ ‎‡9  1‏
919 ‎‡a  safetyandefficacyofdenosumabforadultsandskeletallymatureadolescentswithgiantcelltumourofboneinterimanalysisofanopenlabelparallelgroupphase2study‏ ‎‡A  Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study‏ ‎‡9  1‏
919 ‎‡a  retrospectivesurveyofunselectedhospitalpatientswithandwithoutcancercomparingoutcomesfollowingvenousthromboembolism‏ ‎‡A  Retrospective survey of unselected hospital patients with and without cancer comparing outcomes following venous thromboembolism‏ ‎‡9  1‏
919 ‎‡a  reckinosteosarcomaanovelroleintumourvasculatureandinhibitionoftumorigenesisinanorthotopicmodel‏ ‎‡A  RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model‏ ‎‡9  1‏
919 ‎‡a  reckanewlydiscoveredinhibitorofmetastasiswithprognosticsignificanceinmultipleformsofcancer‏ ‎‡A  RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer‏ ‎‡9  1‏
919 ‎‡a  rb1mediatedcellautonomousandhostdependentoncosuppressormechanismsinradiationinducedosteosarcoma‏ ‎‡A  RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  rankldenosumabandgiantcelltumorofbone‏ ‎‡A  RANKL, denosumab, and giant cell tumor of bone.‏ ‎‡9  1‏
919 ‎‡a  randomizedtrialofaslowreleaseversusastandardformulationofcytarabinefortheintrathecaltreatmentoflymphomatousmeningitis‏ ‎‡A  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.‏ ‎‡9  1‏
919 ‎‡a  psychosocialmorbidityintp53mutationcarriersiswholebodycancerscreeningbeneficial‏ ‎‡A  Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?‏ ‎‡9  1‏
919 ‎‡a  proportionoflungcancersinmalesduetooccupationindifferentareasoftheusa‏ ‎‡A  Proportion of lung cancers in males, due to occupation, in different areas of the USA.‏ ‎‡9  1‏
919 ‎‡a  5fluorouracilapharmacologicalparadigmintheuseofcytotoxics‏ ‎‡A  5-fluorouracil: a pharmacological paradigm in the use of cytotoxics‏ ‎‡9  1‏
919 ‎‡a  candidategeneapproachtosearchingforlowpenetrancebreastandprostatecancergenes‏ ‎‡A  A candidate gene approach to searching for low-penetrance breast and prostate cancer genes‏ ‎‡9  1‏
919 ‎‡a  comparisonofaustralianandfrenchfamiliesaffectedbysarcomaperceptionsofgeneticsandincidentalfindings‏ ‎‡A  A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings‏ ‎‡9  1‏
919 ‎‡a  genomewidescanidentifiesvariantsinnfibassociatedwithmetastasisinpatientswithosteosarcoma‏ ‎‡A  A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  newlycharacterizedhumanwelldifferentiatedliposarcomacelllinecontainsamplificationsofthe12q1221and10p1114regions‏ ‎‡A  A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions.‏ ‎‡9  1‏
919 ‎‡a  phaseib2translationalstudyofsunitinibwithneoadjuvantradiotherapyinsofttissuesarcoma‏ ‎‡A  A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma‏ ‎‡9  1‏
919 ‎‡a  massivelyparallelsequencingassiststhediagnosisandguidedtreatmentofcancersofunknownprimary‏ ‎‡A  Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary‏ ‎‡9  1‏
919 ‎‡a  prolongeddiseasefreesurvivalwithspecificreinductiontherapyinacutemyeloidleukaemiarelapsingfollowingbonemarrowtransplantation‏ ‎‡A  Prolonged disease-free survival with specific re-induction therapy in acute myeloid leukaemia relapsing following bone marrow transplantation‏ ‎‡9  1‏
919 ‎‡a  progressinmanagementofacutemyeloidleukaemiaamlinaustraliasince1980asingleinstitutionretrospectivestudy‏ ‎‡A  Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective study‏ ‎‡9  1‏
919 ‎‡a  progressinmanagementofacutemyeloidleukaemia‏ ‎‡A  Progress in management of acute myeloid leukaemia‏ ‎‡9  1‏
919 ‎‡a  prevailingimportanceofthehedgehogsignalingpathwayandthepotentialfortreatmentadvancementinsarcoma‏ ‎‡A  Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma.‏ ‎‡9  1‏
919 ‎‡a  precisionmedicineforadvancedpancreascancertheindividualizedmolecularpancreaticcancertherapyimpacttrial‏ ‎‡A  Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial‏ ‎‡9  1‏
919 ‎‡a  ppargammaindependentinductionofgrowtharrestandapoptosisinprostateandbladdercarcinoma‏ ‎‡A  PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma‏ ‎‡9  1‏
919 ‎‡a  possibleprocarcinogeniceffectofendotoxinonlungcancerinanextendedfollowupofshanghaiwomentextileworkers‏ ‎‡A  Possible pro-carcinogenic effect of endotoxin on lung cancer in an extended follow-up of Shanghai women textile workers‏ ‎‡9  1‏
919 ‎‡a  phosphoproteomicprofilingrevealsalkandmetasnovelactionabletargetsacrosssynovialsarcomasubtypes‏ ‎‡A  Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes‏ ‎‡9  1‏
919 ‎‡a  patientperspectivesonmoleculartumorprofilingwhywouldntyou‏ ‎‡A  Patient perspectives on molecular tumor profiling: "Why wouldn't you?"‏ ‎‡9  1‏
919 ‎‡a  parathyroidhormonerelatedproteinprotectsagainstmammarytumoremergenceandisassociatedwithmonocyteinfiltrationinductalcarcinomainsitu‏ ‎‡A  Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ.‏ ‎‡9  1‏
919 ‎‡a  outcomesofpatientswithnonmelanomasolidtumoursreceivingselffundedpembrolizumabatchrisobrienlifehouse‏ ‎‡A  Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse‏ ‎‡9  1‏
919 ‎‡a  opticalmappingrevealsahigherlevelofgenomicarchitectureofchainedfusionsincancer‏ ‎‡A  Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer.‏ ‎‡9  1‏
919 ‎‡a  benefitsandadverseeventsinyoungerversusolderpatientsreceivingadjuvantchemotherapyforcoloncancerfindingsfromtheadjuvantcoloncancerendpointsdataset‏ ‎‡A  Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set‏ ‎‡9  1‏
919 ‎‡a  nutlin3aefficacyinsarcomapredictedbytranscriptomicandepigeneticprofiling‏ ‎‡A  Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling‏ ‎‡9  1‏
919 ‎‡a  baselinesurveillancein51fraumenisyndromeusingwholebodymagneticresonanceimagingametaanalysis‏ ‎‡A  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis‏ ‎‡9  1‏
919 ‎‡a  authorcorrectiontherapeuticimplicationsofgermlinegeneticfindingsincancer‏ ‎‡A  Author Correction: Therapeutic implications of germline genetic findings in cancer‏ ‎‡9  1‏
919 ‎‡a  authorcorrectiondiagnosisoffusiongenesusingtargetedrnasequencing‏ ‎‡A  Author Correction: Diagnosis of fusion genes using targeted RNA sequencing‏ ‎‡9  1‏
919 ‎‡a  atypicalewingsarcomabreakpointregion1fluorescenceinsituhybridizationsignalpatternsinboneandsofttissuetumoursdiagnosticexperiencewith135cases‏ ‎‡A  Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases.‏ ‎‡9  1‏
919 ‎‡a  assessingtheclinicalvalueoftargetedmassivelyparallelsequencinginalongitudinalprospectivepopulationbasedstudyofcancerpatients‏ ‎‡A  Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.‏ ‎‡9  1‏
919 ‎‡a  nextgenerationsequenceanalysisofcancerxenograftmodels‏ ‎‡A  Next-generation sequence analysis of cancer xenograft models.‏ ‎‡9  1‏
919 ‎‡a  multiomicsmedicineinoncologyassessingeffectivenesscosteffectivenessandfutureresearchprioritiesforthemolecularlyuniqueindividual‏ ‎‡A  Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual.‏ ‎‡9  1‏
919 ‎‡a  multidisciplinaryapproachtodiagnosisandmanagementofosteosarcomaareviewofthestvincentshospitalexperience‏ ‎‡A  Multidisciplinary approach to diagnosis and management of osteosarcoma - a review of the St Vincent's Hospital experience.‏ ‎‡9  1‏
919 ‎‡a  mtorsignalingorchestratesstressinducedmutagenesisfacilitatingadaptiveevolutionincancer‏ ‎‡A  MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer‏ ‎‡9  1‏
919 ‎‡a  mousemodelsoftumorimmunotherapy‏ ‎‡A  Mouse Models of Tumor Immunotherapy‏ ‎‡9  1‏
919 ‎‡a  monogenicandpolygenicdeterminantsofsarcomariskaninternationalgeneticstudy‏ ‎‡A  Monogenic and polygenic determinants of sarcoma risk: an international genetic study‏ ‎‡9  1‏
919 ‎‡a  molecularprofilingofgiantcelltumorofboneandtheosteoclasticlocalizationofligandforreceptoractivatorofnuclearfactorkappab‏ ‎‡A  Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB‏ ‎‡9  1‏
919 ‎‡a  quantitativemodeltopredictpathogenicityofmissensevariantsinthetp53gene‏ ‎‡A  A quantitative model to predict pathogenicity of missense variants in the TP53 gene‏ ‎‡9  1‏
919 ‎‡a  invivotumormodelexploitingmetabolicresponseasabiomarkerfortargeteddrugdevelopment‏ ‎‡A  An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development‏ ‎‡9  1‏
919 ‎‡a  adolescentsandyoungadultswithcancerthechallenge‏ ‎‡A  Adolescents and young adults with cancer: the challenge‏ ‎‡9  1‏
919 ‎‡a  molecularpathogenesisofosteosarcoma‏ ‎‡A  Molecular pathogenesis of osteosarcoma.‏ ‎‡9  1‏
919 ‎‡a  adolescentandyoungadultoncologyanemergingfield‏ ‎‡A  Adolescent and Young Adult Oncology: An Emerging Field‏ ‎‡9  1‏
919 ‎‡a  adolescentandyoungadultcancerarevolutioninevolution‏ ‎‡A  Adolescent and young adult cancer: a revolution in evolution?‏ ‎‡9  1‏
919 ‎‡a  molecularmedicineaclinicians1onmicroarrays‏ ‎‡A  Molecular medicine: a clinician's primer on microarrays.‏ ‎‡9  1‏
919 ‎‡a  medicalresearchcounciladjuvanttrialinhighgradegliomas‏ ‎‡A  Medical Research Council adjuvant trial in high-grade gliomas‏ ‎‡9  1‏
919 ‎‡a  acceptingriskintheaccelerationofdrugdevelopmentforrarecancers‏ ‎‡A  Accepting risk in the acceleration of drug development for rare cancers‏ ‎‡9  1‏
919 ‎‡a  abstractsofthe10congressoftheeuropeanassociationofneurooncologymarseillefranceseptember69‏ ‎‡A  Abstracts of the 10th Congress of the European Association of NeuroOncology. Marseille, France. September 6-9, 2012‏ ‎‡9  1‏
919 ‎‡a  abstract4593genomewideassociationstudyidentifiesnovellociassociatedwithosteosarcoma‏ ‎‡A  Abstract 4593: Genome-wide association study identifies novel loci associated with osteosarcoma‏ ‎‡9  1‏
919 ‎‡a  vegfjak2stat5axismaypartiallymediateendothelialcelltolerancetohypoxia‏ ‎‡A  A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia‏ ‎‡9  1‏
919 ‎‡a  roleforalphavintegrinsubunitintgfbetastimulatedosteoclastogenesis‏ ‎‡A  A role for alphaV integrin subunit in TGF-beta-stimulated osteoclastogenesis‏ ‎‡9  1‏
919 ‎‡a  mechanismsofbonelossfollowingallogeneicandautologoushemopoieticstemcelltransplantation‏ ‎‡A  Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation‏ ‎‡9  1‏
919 ‎‡a  locallyaggressiveconnectivetissuetumors‏ ‎‡A  Locally Aggressive Connective Tissue Tumors.‏ ‎‡9  1‏
919 ‎‡a  liposarcomamoleculargeneticsandtherapeutics‏ ‎‡A  Liposarcoma: molecular genetics and therapeutics.‏ ‎‡9  1‏
943 ‎‡a  201x‏ ‎‡A  2012‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000081751623‏
996 ‎‡2  LC|n 93095971‏
996 ‎‡2  RERO|A002933788‏
996 ‎‡2  LC|n 2007080988‏
996 ‎‡2  LC|no2008174412‏
996 ‎‡2  PTBNP|1152662‏
996 ‎‡2  ISNI|0000000024906174‏
996 ‎‡2  NUKAT|n 2007006793‏
996 ‎‡2  LC|no2009108939‏
996 ‎‡2  CAOONL|ncf10419327‏
996 ‎‡2  LC|n 89657213‏
996 ‎‡2  DNB|1213666279‏
996 ‎‡2  DNB|172997771‏
996 ‎‡2  ISNI|0000000020370042‏
996 ‎‡2  ISNI|0000000117726607‏
996 ‎‡2  DNB|1342554450‏
996 ‎‡2  LC|no2009192057‏
996 ‎‡2  LC|n 2016047287‏
996 ‎‡2  LC|no2020071188‏
996 ‎‡2  RERO|A012512705‏
996 ‎‡2  N6I|vtls001381760‏
996 ‎‡2  CAOONL|ncf13717068‏
996 ‎‡2  N6I|vtls002760335‏
996 ‎‡2  BIBSYS|2083444‏
996 ‎‡2  J9U|987011245285305171‏
996 ‎‡2  CAOONL|ncf11179516‏
996 ‎‡2  ISNI|0000000000170203‏
996 ‎‡2  N6I|vtls001269102‏
996 ‎‡2  LC|no2002093818‏
996 ‎‡2  NTA|122935411‏
996 ‎‡2  J9U|987007350888505171‏
996 ‎‡2  NUKAT|n 2009075759‏
996 ‎‡2  LC|nb 90481421‏
996 ‎‡2  B2Q|0001222958‏
996 ‎‡2  SUDOC|176564144‏
996 ‎‡2  LC|no2019187223‏
996 ‎‡2  BNF|12180215‏
996 ‎‡2  BIBSYS|2102273‏
996 ‎‡2  LIH|LNB:BW00;=_s__u_‏
996 ‎‡2  NII|DA07225563‏
996 ‎‡2  ISNI|000000011488161X‏
996 ‎‡2  BNF|12445731‏
996 ‎‡2  DNB|115927407X‏
996 ‎‡2  NUKAT|n 2011213460‏
996 ‎‡2  LC|no2022092207‏
996 ‎‡2  ISNI|0000000040304640‏
996 ‎‡2  LC|nb2009012345‏
996 ‎‡2  J9U|987007371189005171‏
996 ‎‡2  NKC|mub2015882565‏
996 ‎‡2  NKC|mub2015882566‏
996 ‎‡2  SUDOC|177078545‏
996 ‎‡2  DNB|1126255688‏
996 ‎‡2  LC|no2004088995‏
996 ‎‡2  J9U|987007421756505171‏
996 ‎‡2  BIBSYS|1671433162549‏
996 ‎‡2  ISNI|0000000083409530‏
996 ‎‡2  CAOONL|ncf11232768‏
996 ‎‡2  J9U|987007273159505171‏
996 ‎‡2  SUDOC|061564052‏
996 ‎‡2  LC|nb2009027136‏
996 ‎‡2  DBC|87097969014372‏
996 ‎‡2  BIBSYS|90360862‏
996 ‎‡2  DNB|1048465853‏
996 ‎‡2  CAOONL|ncf11355668‏
996 ‎‡2  DNB|128978457‏
996 ‎‡2  BNF|13900405‏
996 ‎‡2  CAOONL|ncf11528834‏
996 ‎‡2  SUDOC|241735548‏
996 ‎‡2  LC|nb2009028533‏
996 ‎‡2  ISNI|0000000498160052‏
996 ‎‡2  NTA|104136138‏
996 ‎‡2  SUDOC|05975625X‏
996 ‎‡2  LC|n 2014015468‏
996 ‎‡2  LC|n 81089179‏
996 ‎‡2  DBC|87097969014402‏
996 ‎‡2  NTA|133780708‏
996 ‎‡2  ISNI|000000005047490X‏
996 ‎‡2  LC|nb2010001811‏
996 ‎‡2  LC|no2009012305‏
996 ‎‡2  LC|nb2010001787‏
996 ‎‡2  NTA|142889369‏
996 ‎‡2  CAOONL|ncf10141791‏
996 ‎‡2  BNE|XX969263‏
996 ‎‡2  SUDOC|119708787‏
996 ‎‡2  DNB|1117818349‏
996 ‎‡2  LC|no2008031269‏
996 ‎‡2  LC|no2023038875‏
996 ‎‡2  LC|no2006007162‏
996 ‎‡2  LC|n 95046359‏
996 ‎‡2  LC|n 81015157‏
996 ‎‡2  J9U|987007425858805171‏
996 ‎‡2  RERO|A023028175‏
996 ‎‡2  ISNI|0000000044050289‏
996 ‎‡2  NTA|070113017‏
996 ‎‡2  NUKAT|n 2010175938‏
996 ‎‡2  RERO|A006232203‏
996 ‎‡2  BNF|11926498‏
996 ‎‡2  NKC|mzk2007386133‏
996 ‎‡2  BLBNB|000230639‏
996 ‎‡2  CAOONL|ncf10114978‏
996 ‎‡2  SUDOC|035357983‏
996 ‎‡2  ISNI|000000010480870X‏
996 ‎‡2  NLA|000035886607‏
996 ‎‡2  NTA|300338880‏
996 ‎‡2  NLA|000035546178‏
996 ‎‡2  ISNI|0000000021781716‏
996 ‎‡2  J9U|987007422222105171‏
996 ‎‡2  BNC|981058511214206706‏
996 ‎‡2  LC|no 99023509‏
996 ‎‡2  ISNI|0000000080512663‏
996 ‎‡2  DNB|172997763‏
996 ‎‡2  LC|no 98080769‏
996 ‎‡2  DNB|1013703448‏
996 ‎‡2  LC|no2005099844‏
996 ‎‡2  NLA|000035119462‏
996 ‎‡2  SUDOC|188437916‏
996 ‎‡2  N6I|vtls000024737‏
996 ‎‡2  ISNI|0000000500108000‏
996 ‎‡2  ISNI|000000006741134X‏
996 ‎‡2  ISNI|0000000082826906‏
996 ‎‡2  LC|nb2020000298‏
996 ‎‡2  BIBSYS|5093181‏
996 ‎‡2  CAOONL|ncf10101631‏
996 ‎‡2  DNB|173547419‏
996 ‎‡2  NUKAT|n 2008059092‏
996 ‎‡2  BIBSYS|90650160‏
996 ‎‡2  SUDOC|08598048X‏
996 ‎‡2  NUKAT|n 2012253276‏
996 ‎‡2  BNE|XX4919817‏
996 ‎‡2  LC|n 2002108468‏
996 ‎‡2  BNC|981058509538106706‏
996 ‎‡2  LIH|LNB:C_h__y__c_;=CR‏
996 ‎‡2  BIBSYS|1004662‏
996 ‎‡2  LC|nb2016004940‏
996 ‎‡2  DNB|104798184X‏
996 ‎‡2  BNC|981058618345906706‏
996 ‎‡2  NUKAT|nx2023515984‏
996 ‎‡2  BIBSYS|1592544501960‏
996 ‎‡2  SUDOC|061743356‏
996 ‎‡2  BIBSYS|2057113‏
996 ‎‡2  DNB|108165483X‏
996 ‎‡2  ISNI|0000000075866555‏
996 ‎‡2  J9U|987007388952105171‏
996 ‎‡2  LC|n 2010058197‏
996 ‎‡2  RERO|A027207185‏
996 ‎‡2  ISNI|0000000072465449‏
996 ‎‡2  ISNI|0000000073931384‏
996 ‎‡2  CAOONL|ncf11482291‏
996 ‎‡2  LC|n 88666638‏
996 ‎‡2  LC|nb2020008299‏
996 ‎‡2  LC|n 2003146830‏
996 ‎‡2  ISNI|0000000497408431‏
996 ‎‡2  BNF|14463571‏
996 ‎‡2  LNB|LNC10-000099482‏
996 ‎‡2  LNB|LNC10-000099484‏
996 ‎‡2  CAOONL|ncf11954210‏
996 ‎‡2  LC|nr 93044729‏
996 ‎‡2  DNB|1158712944‏
996 ‎‡2  LC|n 78077448‏
996 ‎‡2  LIH|LNB:C_h__s_X;=CG‏
996 ‎‡2  NTA|069576793‏
996 ‎‡2  PTBNP|1573531‏
996 ‎‡2  DNB|122830180‏
996 ‎‡2  RERO|A027258560‏
996 ‎‡2  ISNI|0000000078511194‏
996 ‎‡2  DNB|1075603579‏
996 ‎‡2  ISNI|0000000037087681‏
996 ‎‡2  NTA|111071119‏
996 ‎‡2  BNC|981058509437306706‏
996 ‎‡2  RERO|A027990583‏
996 ‎‡2  SUDOC|130724068‏
996 ‎‡2  LC|no2012048113‏
996 ‎‡2  SUDOC|266059759‏
996 ‎‡2  DNB|128508531‏
996 ‎‡2  LC|nb2009027124‏
996 ‎‡2  ISNI|0000000045295966‏
996 ‎‡2  ISNI|0000000075822296‏
996 ‎‡2  ISNI|0000000118161986‏
996 ‎‡2  LC|nb2001040395‏
996 ‎‡2  ISNI|0000000498619572‏
996 ‎‡2  SUDOC|174361432‏
996 ‎‡2  LC|n 81093014‏
996 ‎‡2  LC|n 82158579‏
996 ‎‡2  BIBSYS|1593520723938‏
996 ‎‡2  NII|DA17070532‏
996 ‎‡2  SUDOC|06118814X‏
996 ‎‡2  ISNI|000000013519769X‏
996 ‎‡2  ISNI|0000000047343597‏
996 ‎‡2  ISNI|0000000052103854‏
996 ‎‡2  DNB|171471075‏
996 ‎‡2  ISNI|0000000031120145‏
996 ‎‡2  LC|n 98021368‏
996 ‎‡2  NLR|RU NLR AUTH 770181657‏
996 ‎‡2  ISNI|0000000060473310‏
996 ‎‡2  ISNI|0000000384767323‏
996 ‎‡2  DNB|101234648X‏
996 ‎‡2  DNB|135214173‏
996 ‎‡2  BIBSYS|6072474‏
996 ‎‡2  LC|no2007044339‏
996 ‎‡2  BNF|12521476‏
996 ‎‡2  LC|nb2023010170‏
996 ‎‡2  SUDOC|160259126‏
996 ‎‡2  BAV|495_108833‏
996 ‎‡2  NUKAT|n 00057271‏
996 ‎‡2  J9U|987007297544505171‏
996 ‎‡2  ISNI|0000000500526392‏
996 ‎‡2  BNF|15893827‏
996 ‎‡2  SUDOC|204704227‏
996 ‎‡2  CAOONL|ncf11362235‏
996 ‎‡2  ISNI|0000000509867097‏
996 ‎‡2  DNB|1122115032‏
996 ‎‡2  CAOONL|ncf10592978‏
996 ‎‡2  LC|no 00053425‏
996 ‎‡2  CAOONL|ncf10351123‏
996 ‎‡2  LC|n 95113371‏
996 ‎‡2  J9U|987007453519905171‏
996 ‎‡2  J9U|987007321445705171‏
996 ‎‡2  SUDOC|103713166‏
996 ‎‡2  CAOONL|ncf10726476‏
996 ‎‡2  LC|nb 98064753‏
996 ‎‡2  BNF|12466203‏
996 ‎‡2  CAOONL|ncf11470427‏
996 ‎‡2  BIBSYS|90794639‏
996 ‎‡2  RERO|A011524946‏
996 ‎‡2  LC|no2016074397‏
996 ‎‡2  SUDOC|191495328‏
996 ‎‡2  ISNI|0000000082825823‏
996 ‎‡2  SUDOC|034104046‏
996 ‎‡2  LC|n 83301794‏
996 ‎‡2  NTA|339714514‏
996 ‎‡2  NKC|jo20181005687‏
996 ‎‡2  ISNI|0000000114907082‏
996 ‎‡2  LC|n 2010040755‏
996 ‎‡2  SELIBR|232411‏
996 ‎‡2  LC|n 78000737‏
996 ‎‡2  SUDOC|142720445‏
996 ‎‡2  NII|DA05728268‏
996 ‎‡2  LC|no2007043296‏
996 ‎‡2  CAOONL|ncf10556202‏
996 ‎‡2  LC|no2012011479‏
996 ‎‡2  BIBSYS|2045542‏
996 ‎‡2  ISNI|0000000398654290‏
996 ‎‡2  J9U|987007317321805171‏
996 ‎‡2  CAOONL|ncf10371638‏
996 ‎‡2  CAOONL|ncf11607631‏
996 ‎‡2  NTA|320295567‏
996 ‎‡2  LC|nb2009019240‏
996 ‎‡2  ISNI|0000000064505957‏
996 ‎‡2  BNC|981058511214406706‏
996 ‎‡2  CAOONL|ncf11154578‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏